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Introduction
IL-1 plays an important role in the pathogenesis of both
illnesses. The anti-IL1 therapy (anakinra/ canakinumab)
had been proved to be very effective in their treatment.
The infections related to these treatments in children had
been hardly described in literature.
Objectives
To describe the infectious complications in children with
systemic juvenile idiopathic arthritis (SJIA) or autoinflam-
matory diseases (AD) while receiving anti-IL1 drugs.
Methods
All the patients who had received IL1 inhibitors from
January 2005 to January 2014 in our unit were included.
We recorded the length of the exposition to anakinra or
canakinumab, diagnosis, previous exposition to a different
biologic treatment and moderate or severe infections.
The patients with SJIA were defined by the ILAR
criteria. In the AD group were included familiar
mediterranean fever (FMF), Hiper IgD syndrome (HIDS),
tumour necrosis factor receptor-associated periodic fever
syndrome (TRAPS), Cryopyrin-Associated Periodic
Syndrome (CAPS) and 1 pyogenic arthritis, pyoderma
gangrenosum and acne syndrome (PAPA).
Results
Thirty nine patients were identified: 28 SJIAS and 11 AD
(7 HIDS, 2 TRAPS, 1 PAPA, 1 CAPS). Sixteen of them
had received canakinumab, 35 anakinra and 12 had
received both consecutively. Their mean age were
8.7 years (IQR 4.4-13.2).
At least one moderate-severe infection happened in 10/
39 (25%) patients. The mean period from the first dose to
the first infection was 1.78 years (range 0.3-3.75, IQR
1.05-2.65).
In the SJIA group 3/28 (10%) of the patients had at least
one outstanding infection with a total of 7 episodes. In the
AD group 5/11 (45%) developed at least one infection,
with a total of 10 episodes, all of them in patients with
HIDS. The 71% of patients with HIDS had at least one
moderate-severe infection. Three patients accumulated the
52% of the episodes.
While receiving anakinra the infection rate was 11,6
episodes x 100 patients/year of treatment and 14, 4 while
receiving canakinumab (RR 1.2). Table 1.
Conclusion
This study suggests a similar incidence of infections in
both groups of treatment. Nevertheless we have observed
a higher incidence of infections in the AD Group
compared to the SJIA group.
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Table 1
SJIA: 28 patients AD: 11 patients
Canakinumab 1 pneumonia 1 Herpes Zoster
1 Soft tissue infection
1 Recurrent low urinary tract
infection
Anakinra 4 pneumonia 1 pneumonia
1 HPV infection 1 sepsis
1 severe VEB
infection
1 severe herpetic stomatitis
1 Recurrent low urinary tract
infection
2 oropharingeal candidiasis
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